Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares stock (HKPD) is currently trading at $0.66. Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares PS ratio (Price-to-Sales) is 0.34. WallStSmart rates HKPD as Sell.
- HKPD PE ratio analysis and historical PE chart
- HKPD PS ratio (Price-to-Sales) history and trend
- HKPD intrinsic value — DCF, Graham Number, EPV models
- HKPD stock price prediction 2025 2026 2027 2028 2029 2030
- HKPD fair value vs current price
- HKPD insider transactions and insider buying
- Is HKPD undervalued or overvalued?
- Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares financial analysis — revenue, earnings, cash flow
- HKPD Piotroski F-Score and Altman Z-Score
- HKPD analyst price target and Smart Rating
Hong Kong Pharma Digital Technology Holdings
📊 No data available
Try selecting a different time range
Smart Analysis
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, eps growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Earnings per share surging 130.20% year-over-year
Trading at 1.40x book value, attractively priced
Supporting Valuation Data
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -4.70%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 0.78%
Micro-cap company with very limited liquidity and high volatility
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 9.3/10) while 6 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, EPS Growth, Price/Book. Valuation metrics including Price/Sales (0.34), Price/Book (1.40) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 130.20%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -4.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -0.59%, Operating Margin at -9.05%, Profit Margin at -0.13%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -0.59% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -4.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HKPD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HKPD's Price-to-Sales ratio of 0.34x trades 42% below its historical average of 0.59x (10th percentile). The current valuation is 74% below its historical high of 1.32x set in Jan 2025, and 4% above its historical low of 0.33x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.8x as trailing revenue scaled faster than the stock price.
Compare HKPD with Competitors
Top PHARMACEUTICAL RETAILERS stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) · HEALTHCARE › PHARMACEUTICAL RETAILERS
The Big Picture
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares is in a turnaround phase, with management focused on restoring profitability. Revenue reached 20M with 5% decline year-over-year. The company is currently unprofitable, posting a -0.1% profit margin.
Key Findings
The company is unprofitable with a -0.1% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -106,393, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor PHARMACEUTICAL RETAILERS industry trends, competitive moves, and regulatory changes that could impact Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares.
Bottom Line
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares(HKPD)
NASDAQ
HEALTHCARE
PHARMACEUTICAL RETAILERS
USA
Hong Kong Pharma Digital Technology Holdings Limited is a pioneering company at the intersection of biotechnology and digital healthcare, focusing on the integration of cutting-edge technology with pharmaceutical services to enhance patient outcomes and streamline healthcare delivery. Leveraging advanced digital solutions and data analytics, the company optimizes drug development processes and improves operational efficiencies, positioning itself as a critical player in the evolving healthcare landscape. With a strong commitment to health technology advancement and the cultivation of strategic alliances, Hong Kong Pharma is poised to meet the demands of both domestic and global markets while driving innovation across its pharmaceutical service offerings.